Inhibition of Amyloid Formation by a Fragment of MBP

Novel peptides provide a new approach to degrading and disrupting harmful plaques associated with the progression of amyloid diseases such as Cerebral Amyloid Angiopathy and Alzheimer's. Background: The Alzheimer's Association estimates that greater than 5 million Americans suffer from Alzheimer's disease, the most widespread form of dementia. Amyloid beta-proteins assemble into fibrils that form harmful plaques, implicated in the neurological deficiencies associated with Alzheimer's disease. Additionally, other progressive neuro de-generative disorders and amyloid diseases affect both humans and animals. Thus, the aim of current and future research is to offer treatments that reduce the effects of these diseases and extend the average life expectancy of patients. Technology Overview: Dr. William Van Nostrand, professor in the Department of Medicine at Stony Brook University, has developed a new technology that facilitates the breakdown of harmful amyloid fibrils and may prevent the formation of the amyloid plaques associated with the progression of amyloid-based neuro de-generative diseases. The invention utilizes fragments of myelin basic protein that binds to amyloid proteins and inhibits fibril formation. Additionally, the structure of amyloid beta has shown to be altered, allowing for the breakdown of insoluble amyloid beta fibrils. This invention proves promising for the treatment of Alzheimer's disease, among other diseases. Advantages: Novel therapeutic treatment for Alzheimer's patients, among other amyloid-based disorders and prion diseases. Prevents formation of amyloid plaques by targeting in-habilitation of protein-protein interactions. Applications: Neurological disorders Alzheimer's disease Amyloid diseases Prion diseases Intellectual Property Summary: PCT Publication No. WO 2010-024927 Stage of Development: Preclinical Licensing Potential: We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area. Licensing Status: Available for License Additional Information: Amyloid Beta-protein, myelin basic protein fragment, amyloid https://stonybrook.technologypublisher.com/files/sites/therapeutics1.jpg
Patent Information:
Technology/Start-up ID: